Investment
Features
FeesSafety
Academy
More
Pluang+

Compare ADMA Biologics Inc (ADMA) vs Figs Inc (FIGS) Price & Performance

ADMA Biologics IncTrade

Price performance (Past 24H)

Key statistics

ADMA Biologics Inc vs Figs Inc — how do they compare? ADMA Biologics Inc trades at $9.81 (market cap $2.18B), while Figs Inc trades at $14.26 (market cap $2.39B). The key difference: ADMA Biologics Inc and Figs Inc are close in size by market cap, and Figs Inc is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.

ADMAFIGS
Market Cap
$2.18B$2.39B
Sector
HealthConsumer Cyclical
52-Week High
$20.38$17.12
52-Week Low
$7.60$6.57
Enterprise Value
$2.25B$2.15B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

ADMA Biologics Inc

ADMA trades at $9.90, down 1.59% today, with strong profitability metrics including 64.71% gross margin and 41.9% ROE. Technical indicators show a bullish trend with support at $9-10, though RSI levels suggest overbought conditions. Recent earnings show mixed results with Q4 2025 beating expectations but Q1 and Q2 2026 missing estimates. The stock faces significant legal headwinds with multiple securities fraud lawsuits filed against the company.

Despite strong fundamentals and bullish analyst consensus (88.9% buy ratings), ADMA faces substantial legal risks from ongoing securities litigation that could impact shareholder value. The company's solid profit margins and growth trajectory provide upside potential, but investors should carefully weigh litigation risks against fundamental strength.

Figs Inc

FIGS stock surged 26.87% to $14.26, supported by strong Q2 2026 earnings that beat estimates with $0.11 EPS and 29% revenue growth. The technical outlook is bullish with moving averages aligned positively, while fundamentals show improving profitability with a net income margin of 8.72% and robust gross margins near 69%. Recent news highlights institutional buying and raised full-year guidance, reflecting strong operational momentum.

The outlook remains positive given consistent earnings beats and upward revenue revisions, though the stock's high P/E of 43.21 suggests premium valuation risks. Key investor risks include cost pressures from tariffs and freight, alongside competitive threats in the healthcare apparel space. Analyst consensus is bullish with a $19.50 price target, indicating potential upside from current levels.

Returns comparison

Trailing returns across standard periods

About ADMA Biologics Inc

ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.

Read more on ADMA

About Figs Inc

FIGS Inc is a healthcare apparel company. It offers more fitted scrubs for men and women made of its proprietary fabric FIONx, which provides four-way stretch and has anti-odor, anti-wrinkle, and moisture-wicking properties.

Read more on FIGS